Vir Biotechnology Inc. has announced the initiation of a Phase 1 clinical trial for VIR-5525, an investigational dual-masked T-cell engager targeting the epidermal growth factor receptor (EGFR). The study will assess the safety, pharmacokinetics, and preliminary anti-tumor activity of VIR-5525 as both a monotherapy and in combination with pembrolizumab. The trial aims to address EGFR-expressing solid tumors, such as non-small cell lung cancer, colorectal cancer, head and neck squamous cell carcinoma, and cutaneous squamous cell carcinoma. Initial results from this trial have not yet been presented. The development of VIR-5525 is part of Vir Biotechnology's efforts to provide innovative therapies for hard-to-treat cancers, utilizing the PRO-XTEN™ platform to improve therapeutic outcomes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.